Spyre Therapeutics (SYRE) Operating Expenses (2015 - 2026)

Spyre Therapeutics (SYRE) has 12 years of Operating Expenses data on file, last reported at $45.6 million in Q1 2026.

• Quarterly Operating Expenses fell 14.8% year-over-year to $45.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $201.6 million (down 5.94% YoY) and the FY2025 annual result came in at $209.6 million, changed 0.48% from the prior year.
• Operating Expenses fell to $45.6 million in Q1 2026, from $57.2 million in the prior quarter.
• In the past five years, Operating Expenses ranged from a high of $159.9 million in Q2 2023 to a low of $18.3 million in Q3 2023.
• A 5-year average of $46.7 million and a median of $45.6 million in 2026 frame the typical range for Operating Expenses.
• Annual changes were most pronounced in 2023 — Operating Expenses jumped 593.92% — and 2024, when it plunged 72.4%.
• Tracing SYRE's Operating Expenses over 5 years: stood at $19.3 million in 2022, then surged by 137.53% to $45.9 million in 2023, then soared by 33.41% to $61.3 million in 2024, then retreated by 6.66% to $57.2 million in 2025, then declined by 20.17% to $45.6 million in 2026.
• The last three Operating Expenses figures came in at $45.6 million (Q1 2026), $57.2 million (Q4 2025), and $56.9 million (Q3 2025), per Business Quant data.